Education
About Us
Working with TipRanks
Follow Us
Vericel Corp (VCEL)
NASDAQ:VCEL
VCEL Stock Chart & Stats
$37.64
$1.36(2.35%)
At close: 4:00 PM EST
$37.64
$1.36(2.35%)
Day’s Range― - ―
52-Week Range$29.24 - $63.00
Previous CloseN/A
Volume83.17K
Average Volume (3M)845.02K
Market Cap
$1.83B
Enterprise Value$2.13B
Total Cash (Recent Filing)$135.38M
Total Debt (Recent Filing)$98.01M
Price to Earnings (P/E)290.7
Beta1.21
Next Earnings
Feb 26, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding50,460,205
10 Day Avg. Volume667,266
30 Day Avg. Volume845,017
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)9.19
Price to Sales (P/S)11.31
P/FCF Ratio-461.58
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue8.22
Enterprise Value/Gross Profit11.14
Enterprise Value/Ebitda89.46
Forecast
1Y Price Target
$54.20Price Target Upside44.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceVericel Corporation's MACI and Burn Care segments outperformed in the third quarter, helping alleviate concerns about the steep revenue ramp required for the fourth quarter.
Growth ProspectsThe company is viewed as a rare 19-20%+ growth opportunity with inflecting profitability, contributing to the analyst's recommendation.
Revenue And ProfitabilityThe price target for Vericel Corporation has been increased to $50, reflecting confidence in its 20%+ growth prospects and accelerating profitability.
Bears Say
Government And Regulatory ImpactThe government shutdown puts a pause on the BARDA RFP process and thus potential related Nexobrid revenue upside.
Market PerformanceVCEL shares are down approximately 42% year-to-date following two softer quarters, indicating performance challenges.
Strategic ChallengesThe planned merger between Ocugen's OrthoCellix subsidiary and Carisma Therapeutics was terminated due to insufficient funding by Ocugen.
Vericel News
VCEL FAQ
What was Vericel Corp’s price range in the past 12 months?
Vericel Corp lowest stock price was $29.24 and its highest was $63.00 in the past 12 months.
What is Vericel Corp’s market cap?
Vericel Corp’s market cap is $1.83B.
When is Vericel Corp’s upcoming earnings report date?
Vericel Corp’s upcoming earnings report date is Feb 26, 2026 which is in 77 days.
How were Vericel Corp’s earnings last quarter?
Vericel Corp released its earnings results on Nov 06, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of -$0.006 by $0.106.
Is Vericel Corp overvalued?
According to Wall Street analysts Vericel Corp’s price is currently Undervalued.
Does Vericel Corp pay dividends?
Vericel Corp does not currently pay dividends.
What is Vericel Corp’s EPS estimate?
Vericel Corp’s EPS estimate is 0.39.
How many shares outstanding does Vericel Corp have?
Vericel Corp has 50,460,205 shares outstanding.
What happened to Vericel Corp’s price movement after its last earnings report?
Vericel Corp reported an EPS of $0.1 in its last earnings report, beating expectations of -$0.006. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Vericel Corp?
Currently, no hedge funds are holding shares in VCEL
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$54.20 (44.00% Upside)
$54.20 (44.00% Upside)
Hedge Fund Trend
Increased
By 272.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $189.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.6%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.15%
12-Months-Change
Fundamentals
Return on Equity
4.52%
Trailing 12-Months
Asset Growth
15.60%
Trailing 12-Months
Company Description
Vericel Corp
Vericel Corporation (NASDAQ: VCEL) is a biotechnology company focused on developing and commercializing cell-based therapies for the treatment of patients with serious diseases and conditions. The company operates primarily in the regenerative medicine sector, specializing in products that promote the healing of damaged tissues. Vericel's core products include MACI®, a cell therapy for the repair of cartilage in the knee, and Epicel®, a cultured epidermal autograft for the treatment of severe burns. Through its innovative approach, Vericel aims to improve patient outcomes and quality of life.
VCEL Company Deck
VCEL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Vericel's strong financial performance with record revenue and profit growth, driven by the success of MACI and the launch of MACI Arthro. However, there are potential challenges related to government processes and reimbursement policies that could impact future growth.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$54.20
▲(44.00% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---